Yang B, Zhong C, Peng Y et al (2010) Molecular mechanisms of “off-on switch” of activities of human IDH1 by tumor-associated mutation R132H. Cell Res 20(11):1188–1200. https://doi.org/10.1038/cr.2010.145

Article  CAS  PubMed  Google Scholar 

Scagliola A, Mainini F, Cardaci S (2020) The tricarboxylic acid cycle at the crossroad between cancer and immunity. Antioxid Redox Signal 32(12):834–852. https://doi.org/10.1089/ars.2019.7974

Article  CAS  PubMed  Google Scholar 

Dang L, Yen K, Attar EC (2016) IDH mutations in cancer and progress toward development of targeted therapeutics. Ann Oncol 27(4):599–608. https://doi.org/10.1093/annonc/mdw013

Article  CAS  PubMed  Google Scholar 

Cho NS, Hagiwara A, Eldred BSC et al (2022) Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas. Neuro-oncol Adv 4(1):124. https://doi.org/10.1093/noajnl/vdac124

Article  Google Scholar 

Khairy RA, Momtaz EM, Abdelaziz AM, Shibel PE (2024) Evaluation of immunohistochemical expression of ALK-1 in gliomas, WHO grade 4 and its correlation with IDH1-R132H mutation status. Asian Pac J Cancer Prev 25(1):317–323. https://doi.org/10.31557/apjcp.2024.25.1.317

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gangat N, McCullough K, Abdelmagid M et al (2024) Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia. Haematologica 109(1):187–292. https://doi.org/10.3324/haematol.2023.283732

Article  CAS  PubMed  Google Scholar 

DiNardo CD, Ravandi F, Agresta S et al (2015) Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol 90(8):732–736. https://doi.org/10.1002/ajh.24072

Article  CAS  PubMed  PubMed Central  Google Scholar 

Trovarelli G, Sbaraglia M, Angelini A et al (2024) Are IDH1 R132 mutations associated with poor prognosis in patients with chondrosarcoma of the bone? Clin Orthop Relat Res. https://doi.org/10.1097/CORR.0000000000002960

Article  PubMed  PubMed Central  Google Scholar 

Li J, Qin Z, Li Y et al (2024) Phosphorylation of IDH1 facilitates progestin resistance in endometrial cancer. Adv Sci (Weinh). https://doi.org/10.1002/advs.202310208

Article  PubMed  PubMed Central  Google Scholar 

Borger DR, Tanabe KK, Fan KC et al (2012) Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 17(1):72–79. https://doi.org/10.1634/theoncologist.2011-0386

Article  CAS  PubMed  Google Scholar 

Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807–1812. https://doi.org/10.1126/science.1164382

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu Y, Xu W, Li M et al (2023) The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer. Acta Pharm Sin B 13(4):1438–1466. https://doi.org/10.1016/j.apsb.2022.12.019

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cairns RA, Mak TW (2013) Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov 3(7):730–741. https://doi.org/10.1158/2159-8290.CD-13-0083

Article  CAS  PubMed  Google Scholar 

Dang L, White DW, Gross S et al (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462(7274):739–744. https://doi.org/10.1038/nature08617

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tian W, Zhang W, Wang Y et al (2022) Recent advances of IDH1 mutant inhibitor in cancer therapy. Front Pharmacol 13:982424. https://doi.org/10.3389/fphar.2022.982424

Article  CAS  PubMed  PubMed Central  Google Scholar 

Casak SJ, Pradhan S, Fashoyin-Aje LA et al (2022) FDA approval summary: ivosidenib for the treatment of patients with advanced unresectable or metastatic, chemotherapy refractory cholangiocarcinoma with an IDH1 mutation. Clin Cancer Res 28(13):2733–2737. https://doi.org/10.1158/1078-0432.CCR-21-4462

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mishra SK, Millman SE, Zhang L (2023) Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets. Blood 141(10):1119–1135. https://doi.org/10.1182/blood.2022018092

Article  CAS  PubMed  Google Scholar 

Shafiq M, Sherwani ZA, Mushtaq M et al (2024) A deep learning-based theoretical protocol to identify potentially isoform-selective PI3Kalpha inhibitors. Mol Divers 28(4):1907–1924. https://doi.org/10.1007/s11030-023-10799-0

Article  CAS  PubMed  Google Scholar 

Jiao F, Bao Y, Li M et al (2023) Unraveling the mechanism of ceftaroline-induced allosteric regulation in penicillin-binding protein 2a: insights for novel antibiotic development against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 67(12):e0089523. https://doi.org/10.1128/aac.00895-23

Article  CAS  PubMed  Google Scholar 

Yang J, Fu B, Gou R et al (2024) Molecular mechanism-driven discovery of novel small molecule inhibitors against drug-resistant SARS-CoV-2 M(pro) variants. J Chem Inf Model 64(20):7998–8009. https://doi.org/10.1021/acs.jcim.4c01206

Article  CAS  PubMed  Google Scholar 

Zhao H (2024) The science and art of structure-based virtual screening. ACS Med Chem Lett 15(4):436–440. https://doi.org/10.1021/acsmedchemlett.4c00093

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li M, Li M, Guo J (2022) Molecular mechanism of Ca(2+) in the allosteric regulation of human parathyroid hormone receptor-1. J Chem Inf Model 62(21):5110–5119. https://doi.org/10.1021/acs.jcim.1c00471

Article  CAS  PubMed  Google Scholar 

Wang Y, Tang S, Lai H et al (2020) Discovery of novel IDH1 inhibitor through comparative structure-based virtual screening. Front Pharmacol 11:579768. https://doi.org/10.3389/fphar.2020.579768

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu C, Zeng Z, Ma D et al (2022) Discovery of novel IDH1-R132C inhibitors through structure-based virtual screening. Front Pharmacol 13:982375. https://doi.org/10.3389/fphar.2022.982375

Article  CAS  PubMed  PubMed Central  Google Scholar 

Catacutan DB, Alexander J, Arnold A et al (2024) Machine learning in preclinical drug discovery. Nat Chem Biol 20(8):960–973. https://doi.org/10.1038/s41589-024-01679-1

Article  CAS  PubMed  Google Scholar 

Greener JG, Kandathil SM, Moffat L et al (2022) A guide to machine learning for biologists. Nat Rev Mol Cell Biol 23(1):40–55. https://doi.org/10.1038/s41580-021-00407-0

Article  CAS  PubMed  Google Scholar 

Kumari R, Dalal V (2022) Identification of potential inhibitors for LLM of Staphylococcus aureus: structure-based pharmacophore modeling, molecular dynamics, and binding free energy studies. J Biomol Struct Dyn 40(20):9833–9847. https://doi.org/10.1080/07391102.2021.1936179

Article  CAS  PubMed